Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
As shown by table, males had significantly higher median (25th,75th) BUN, creatinine, uric acid, urine creatinine and urine phosphorous (15.8 (14.15,18.45) mg/dl, 1.1(1,1.25) mg/dl, 6.3 (5.65,7.25) mg/dl, 1538 (1150,1789.5) mg/24 h, 832 (663.75,1163.5) mg/24 h, respectively) than in females (14 (11.8,16.3) mg/dl, 0.8 (0.8,0.9) mg/dl, 4.4 (3.3,5.3) mg/dl, 1011 (725,1273.5) mg/24 h, 671 (484.5,814.5) mg/24 h, respectively) (p < 0.05).Comparison of clinical parameters and lab data between male and female in nephrolithiasis patientsClinical parametersTotalMale patientsFemale patientsp-valueMedian(25th: 75th)Median(25th: 75th)Median(25th: 75th)Age(years)47.5 ± 11.9450.19 ± 12.4345.04 ± 11.170.15BMI(Kg/m2)28.94 ± 4.2128.65 ± 4.9029.2 ± 3.560.67Lab data OPG(pmol/l)3.5(2.9 to 4)3.4(2.9 to 4.3)3.6(2.8 to 3.9)0.61 sRANKL(pmol/l)0.2(0.1 to 0.3)0.2(0.1 to 0.3)0.2(0.1 to 0.3)0.85 BUN(mg/dl)15.2(12.98 to 17.38)15.8(14.15 to 18.45)14(11.8 to 16.3)0.02 Creatinie (mg/dl)0.9(0.8 to 1.1)1.1(1 to 1.25)0.8(0.8 to 0.9)≤ 0.001 Uric acid (mg/dl)5.45(4.03 to 6.3)6.3(5.65 to 7.25)4.4(3.3 to 5.3)≤ 0.001 Ca(mg/dl)9.6(8.9 to 9.98)9.7(8.95 to 10.05)9.5(8.9 to 9.9)0.2 P(mg/dl)3.4(3.13 to 4.18)3.3(3 to 4)3.6(3.3 to 4.2)0.19 Urine volume(ml/24 h)1350(900 to 2237.5)1650(950 to 2237.5)1150(825 to 2250)0.39 Urine creatinine(mg/24 h)1227(949.5 to 1624)1538(1150 to 1789.5)1011(725 to 1273.5)0.003 Urine uric acid(mg/24 h)593(405 to 804.5)786(436 to 865.25)547(390 to 760.5)0.14 Urine calcium (mg/24 h)209.5(150 to 327)193.5(152.5 to 285)232(105 to 340.5)0.9 Urine phosphorus (mg/24 h)741.5(592.5 to 958)832(663.75 to 1163.5)671(484.5 to 814.5)0.04 PTH(pg/ml)32.9(24.65 to 42.83)36.1(27.1 to 41.8)31.1(20.7 to 61.4)0.5 Vitamin D(nmol/l)36.8(25.45 to 61.10)40(27.1 to 56.7)31.55(20.5 to 64.45)0.41 Urine citrate (mg/24 h)493(267 to 740)427(277 to 674)592(225 to 756.25)0.3 Na(mEq/l)137.4(136.8 to 138.35)137.3(136.75 to 138)137.5(136.8 to 139)0.5 eGFR (ml/minute)102.48(82.27 to 119.33)101.98(79.14 to 117.83)103.62(82.43 to 125.85)0.71 kidney stone disease duration (year)3.5(1, 11)3.25(1 to 8.88)4.5(1 to 11.5)0.66eGFR estimated glomerular filtration rate based on the Creatinine Cockcroft-Gault Equation
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Participants were excluded if they had hyperparathyroidism, thyroid gland dysfunction, renal tubular acidosis, malignancy, longstanding corticosteroid intake.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis
Study design awaiting verification · BMC Nephrology · 2018
Original publication title
Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis
© The Author(s). 2018
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Nephrolithiasis is a risk factor for Osteopenia and osteoporosis. Receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin (OPG) regulate bone remodeling and osteoclastogenesis. This study aimed to evaluate the relation between serum OPG, RANKL concentration, and bone mineral density (BMD) in patients with kidney stone disease.
Source: BackgroundAbstract: What methods does the paper describe?
Forty-four nephrolithiasis patients with either low bone mass or normal BMD (considered control group) were enrolled in this study. BMD was measured at lumbar spine (L1-L4) and femoral neck by dual-energy X-ray absorptiometry (DEXA). The serum OPG and RANKL were determined using the ELISA method.
Source: MethodsAbstract: Results
The median levels of serum OPG were significantly higher in nephrolithiasis patients with low bone mass compared to the nephrolithiasis patients with normal BMD (3.9 pmol/l versus 3.1 pmol/l; P = 0.03), respectively. Negative correlation was detected between bone densities of femoral neck and OPG in patients with nephrolithiasis (r = −.0344, P = 0.02).
Source: ResultsAbstract: Conclusion
The present study showed that high serum fasting OPG levels may be indicative of femoral neck BMD in patients with nephrolithiasis.
Source: ConclusionAuthors’ abstract
Background
Nephrolithiasis is a risk factor for Osteopenia and osteoporosis. Receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin (OPG) regulate bone remodeling and osteoclastogenesis. This study aimed to evaluate the relation between serum OPG, RANKL concentration, and bone mineral density (BMD) in patients with kidney stone disease.
Methods
Forty-four nephrolithiasis patients with either low bone mass or normal BMD (considered control group) were enrolled in this study. BMD was measured at lumbar spine (L1-L4) and femoral neck by dual-energy X-ray absorptiometry (DEXA). The serum OPG and RANKL were determined using the ELISA method.
Results
The median levels of serum OPG were significantly higher in nephrolithiasis patients with low bone mass compared to the nephrolithiasis patients with normal BMD (3.9 pmol/l versus 3.1 pmol/l; P = 0.03), respectively. Negative correlation was detected between bone densities of femoral neck and OPG in patients with nephrolithiasis (r = −.0344, P = 0.02).
Conclusion
The present study showed that high serum fasting OPG levels may be indicative of femoral neck BMD in patients with nephrolithiasis.
Publication and source details
Original title: Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis
Asieh Mansour; Maryam Aboeerad; Mostafa Qorbani; Amir Pejman Hashemi Taheri; Mohamad Pajouhi; Abbas Ali Keshtkar; Bagher Larijani; Mohammad Reza Mohajeri-Tehrani; Mohammad Reza Ganji
BMC Nephrology · 2018
© The Author(s). 2018https://creativecommons.org/licenses/by/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.http://dx.doi.org/10.13039/501100004484Tehran University of Medical Sciences and Health Services26129Ganji Mohammad RezaRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T19:04:00.186877+00:00
DOI: 10.1186/s12882-018-0960-z · PMC6042206